Literature DB >> 21636855

p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages.

Céline Cudejko1, Kristiaan Wouters, Lucía Fuentes, Sarah Anissa Hannou, Charlotte Paquet, Kadiombo Bantubungi, Emmanuel Bouchaert, Jonathan Vanhoutte, Sébastien Fleury, Patrick Remy, Anne Tailleux, Giulia Chinetti-Gbaguidi, David Dombrowicz, Bart Staels, Réjane Paumelle.   

Abstract

The CDKN2A locus, which contains the tumor suppressor gene p16(INK4a), is associated with an increased risk of age-related inflammatory diseases, such as cardiovascular disease and type 2 diabetes, in which macrophages play a crucial role. Monocytes can polarize toward classically (CAMϕ) or alternatively (AAMϕ) activated macrophages. However, the molecular mechanisms underlying the acquisition of these phenotypes are not well defined. Here, we show that p16(INK4a) deficiency (p16(-/-)) modulates the macrophage phenotype. Transcriptome analysis revealed that p16(-/-) BM-derived macrophages (BMDMs) exhibit a phenotype resembling IL-4-induced macrophage polarization. In line with this observation, p16(-/-) BMDMs displayed a decreased response to classically polarizing IFNγ and LPS and an increased sensitivity to alternative polarization by IL-4. Furthermore, mice transplanted with p16(-/-) BM displayed higher hepatic AAMϕ marker expression levels on Schistosoma mansoni infection, an in vivo model of AAMϕ phenotype skewing. Surprisingly, p16(-/-) BMDMs did not display increased IL-4-induced STAT6 signaling, but decreased IFNγ-induced STAT1 and lipopolysaccharide (LPS)-induced IKKα,β phosphorylation. This decrease correlated with decreased JAK2 phosphorylation and with higher levels of inhibitory acetylation of STAT1 and IKKα,β. These findings identify p16(INK4a) as a modulator of macrophage activation and polarization via the JAK2-STAT1 pathway with possible roles in inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636855      PMCID: PMC3677739          DOI: 10.1182/blood-2010-10-313106

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology.

Authors:  De'Broski R Herbert; Christoph Hölscher; Markus Mohrs; Berenice Arendse; Anita Schwegmann; Magda Radwanska; Mosiuoa Leeto; Richard Kirsch; Pauline Hall; Horst Mossmann; Björn Claussen; Irmgard Förster; Frank Brombacher
Journal:  Immunity       Date:  2004-05       Impact factor: 31.745

Review 2.  The chemokine system in diverse forms of macrophage activation and polarization.

Authors:  Alberto Mantovani; Antonio Sica; Silvano Sozzani; Paola Allavena; Annunciata Vecchi; Massimo Locati
Journal:  Trends Immunol       Date:  2004-12       Impact factor: 16.687

3.  Acetylation of Stat1 modulates NF-kappaB activity.

Authors:  Oliver H Krämer; Daniela Baus; Shirley K Knauer; Stefan Stein; Elke Jäger; Roland H Stauber; Manuel Grez; Edith Pfitzner; Thorsten Heinzel
Journal:  Genes Dev       Date:  2006-02-15       Impact factor: 11.361

4.  Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation.

Authors:  Divya Vats; Lata Mukundan; Justin I Odegaard; Lina Zhang; Kristi L Smith; Christine R Morel; Roger A Wagner; David R Greaves; Peter J Murray; Ajay Chawla
Journal:  Cell Metab       Date:  2006-07       Impact factor: 27.287

5.  The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity.

Authors:  Bu Young Choi; Hong Seok Choi; Kwangseok Ko; Yong-Yeon Cho; Feng Zhu; Bong Seok Kang; Svetlana P Ermakova; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Nat Struct Mol Biol       Date:  2005-07-10       Impact factor: 15.369

6.  Modulation of CSF-1-regulated post-natal development with anti-CSF-1 antibody.

Authors:  Suwen Wei; Daniel Lightwood; Heather Ladyman; Sue Cross; Helen Neale; Meryn Griffiths; Ralph Adams; Diane Marshall; Alastair Lawson; Andrew J McKnight; E Richard Stanley
Journal:  Immunobiology       Date:  2005       Impact factor: 3.144

Review 7.  Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.

Authors:  Jo A Van Ginderachter; Kiavash Movahedi; Gholamreza Hassanzadeh Ghassabeh; Sofie Meerschaut; Alain Beschin; Geert Raes; Patrick De Baetselier
Journal:  Immunobiology       Date:  2006-07-21       Impact factor: 3.144

8.  Ink4a/Arf expression is a biomarker of aging.

Authors:  Janakiraman Krishnamurthy; Chad Torrice; Matthew R Ramsey; Grigoriy I Kovalev; Khalid Al-Regaiey; Lishan Su; Norman E Sharpless
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

9.  Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression.

Authors:  H L Dickensheets; C Venkataraman; U Schindler; R P Donnelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

Review 10.  INK4a/ARF: a multifunctional tumor suppressor locus.

Authors:  Norman E Sharpless
Journal:  Mutat Res       Date:  2005-08-25       Impact factor: 2.433

View more
  38 in total

Review 1.  Forging a signature of in vivo senescence.

Authors:  Norman E Sharpless; Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

2.  Basic research: Killing the old: cell senescence in atherosclerosis.

Authors:  Martin R Bennett; Murray C H Clarke
Journal:  Nat Rev Cardiol       Date:  2016-12-12       Impact factor: 32.419

3.  Macrophage-Secreted TNFα and TGFβ1 Influence Migration Speed and Persistence of Cancer Cells in 3D Tissue Culture via Independent Pathways.

Authors:  Ran Li; Jess D Hebert; Tara A Lee; Hao Xing; Alexandra Boussommier-Calleja; Richard O Hynes; Douglas A Lauffenburger; Roger D Kamm
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

4.  Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma.

Authors:  Hye Eun Park; Jung Ho Kim; Nam-Yun Cho; Hye Seung Lee; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2017-06-08       Impact factor: 4.064

5.  Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.

Authors:  Tatiana M Garcia-Bates; Eun Kim; Fernando Concha-Benavente; Sumita Trivedi; Robbie B Mailliard; Andrea Gambotto; Robert L Ferris
Journal:  J Immunol       Date:  2016-02-05       Impact factor: 5.422

Review 6.  Senescent cells: a therapeutic target for cardiovascular disease.

Authors:  Bennett G Childs; Hu Li; Jan M van Deursen
Journal:  J Clin Invest       Date:  2018-04-02       Impact factor: 14.808

7.  Acetylation and sumoylation control STAT5 activation antagonistically.

Authors:  Oliver H Krämer; Richard Moriggl
Journal:  JAKSTAT       Date:  2012-07-01

Review 8.  Identification of shared genetic susceptibility locus for coronary artery disease, type 2 diabetes and obesity: a meta-analysis of genome-wide studies.

Authors:  Chaoneng Wu; Yunguo Gong; Jie Yuan; Hui Gong; Yunzeng Zou; Junbo Ge
Journal:  Cardiovasc Diabetol       Date:  2012-06-14       Impact factor: 9.951

9.  Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development.

Authors:  Kristiaan Wouters; Céline Cudejko; Marion J J Gijbels; Lucia Fuentes; Kadiombo Bantubungi; Jonathan Vanhoutte; Rebecca Dièvart; Charlotte Paquet; Emmanuel Bouchaert; Sarah Anissa Hannou; Florence Gizard; Anne Tailleux; Menno P J de Winther; Bart Staels; Réjane Paumelle
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

10.  Effect of angiotensin II type 2 receptor-interacting protein on adipose tissue function via modulation of macrophage polarization.

Authors:  Fei Jing; Masaki Mogi; Li-Juan Min; Kousei Ohshima; Hirotomo Nakaoka; Kana Tsukuda; Xiaoli Wang; Jun Iwanami; Masatsugu Horiuchi
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.